Lightnews — Scholar-powered news

Dr. John Cush @rheumnow.bsky.social · 13h

🎓 Learning just got smarter.
Every week, RheumIQ challenges you with a quick quiz on current rheumatology updates.
💡 Educational
🎯 Evidence-based
🧠 Addictive (in a good way)
Try it now and level up your clinical knowledge: buff.ly/KI7jFdp

Dr. John Cush @rheumnow.bsky.social · 1d

Prediction of D2T-RA. Model was trained on BRASS pts (700; 16% w/ D2T-RA) & validated on CERTAIN pts (2,070; 28% D2TRA). PRO's strongest predictors. Mod. predictive accuracy (C-index ~0.63) w/ functional status, pain, fatigue, & global Dz activity acrjournals.onlinelibrary.wiley.com/doi/abs/10.1...

Dr. John Cush @rheumnow.bsky.social · 1d

Taiwan study of HBV or HCV reactivation w/ bDMARD use in PsO & PsA - among 5527 treatment episodes (3197 ts/bDMARDs) found a 10% risk of reactivation of HBVr (10.6%) & HCV (9.9%), highest w/ TNFi. Reactivation assoc w/ TNFi, HBsAg+, HBeAg+, www.sciencedirect.com/science/arti...

www.sciencedirect.com

1

Dr. John Cush @rheumnow.bsky.social · 1d

Sonelokimab (SLK) is a nanobody that inhibits IL-17 A&F. Phase 2 ARGO trial 207 active PsA pts Rx w/ SLK 120-mg or 60-mg q4wks or PBO or adalimumab. ACR50 at wk 12 was 60-mg WI=46%; 120-mg WI=46%; PBO 20%. PASI90: 60mg 77% vs 120mg 59% vs PBO 15% www.nature.com/articles/s41...

Sonelokimab, an IL-17A/IL-17F-inhibiting nanobody for active psoriatic arthritis: a randomized, placebo-controlled phase 2 trial - Nature Medicine

In the double-blind, placebo-controlled phase 2 ARGO trial, patients with active psoriatic arthritis treated with a nanobody targeting IL-17A and IL-17F showed substantially better disease response…

www.nature.com

1

Dr. John Cush @rheumnow.bsky.social · 1d

NY Times on Osteoporosis in Men

The NY Times has addressed the problem of osteoporosis in men noting a need for increased awareness and screening...

Read more: buff.ly/I3No8GB

Dr. John Cush @rheumnow.bsky.social · 1d

Gender Complexities in Psoriatic Arthritis Treatment Outcomes

Analysis of a German psoriatic arthritis (PsA) patients registry demonstrates sex-specific differences regarding clinical manifestation and treatment outcomes, especially with regard to drug discontinuations.

buff.ly/BCaRQnH

Dr. John Cush @rheumnow.bsky.social · 1d

From the plenary to posters, RheumNow is your companion for ACR Convergence 2025. Expect:
• KOL videos
• Clinical trial highlights
• Daily faculty recaps
• Live streaming
#ACR25 #Rheumatology #ClinicalTrials

Dr. John Cush @rheumnow.bsky.social · 2d

HMGCR Abs is assoc w/ necrotizing myopathy. Review 78 pts w/ HMGCR IMNM. 31 had overlap w/ higher MMT-score, less muscle weakness, more ILD, arthralgia, wt loss & rash. 12 had musc. dystrophy like dz w/ earlier onset, longer duration, less myalgia & extramuscular Sxs www.nature.com/articles/s41...

Clinical-pathologic classification of anti-HMGCR-positive immune-mediated necrotizing myopathy - Scientific Reports

Scientific Reports - Clinical-pathologic classification of anti-HMGCR-positive immune-mediated necrotizing myopathy

www.nature.com

Dr. John Cush @rheumnow.bsky.social · 2d

Not all difficult-to-treat RA will have rapid radiographic progression

A study of radiographic outcomes in difficult-to-treat rheumatoid arthritis (D2T RA) and poly-refractory RA (pr-RA) show a subset in whom damage is rapid and in need of more aggressive therapy.

buff.ly/xI90TLN

Dr. John Cush @rheumnow.bsky.social · 2d

Review of GLP-1 agonist use in rheumatology - with benefits beyond DM, obesity, improved survival, reduced major cardiovascular and renal events. Anti-inflammatory & chondroprotective effx shown benefit in knee OA & pain. GLP-1RAs do not prevent gout attacks. www.nature.com/articles/s41...

Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions - Nature Reviews Rheumatology

Evidence is emerging that glucagon-like peptide-1 (GLP-1) receptor agonists have anti-inflammatory and chondroprotective properties independent of their effects on weight loss. In this Review, the…

www.nature.com

3

Dr. John Cush @rheumnow.bsky.social · 2d

Retrospective study of 42 adult Still' pts Rx after 2010 w/ IL‐1 inhib if given < 6 mos (early) or > 6mos of Sxs. Early IL-1i had more inactive dz (67% vs 38%; P = 0.17) & steroid d/c w/in 6 mos. 10 major flares observed (62% after IL‐1i suspension or spacing) pmc.ncbi.nlm.nih.gov/articles/PMC...

Early IL‐1 Inhibition in Still's Disease: A Window of Opportunity for Improving Outcomes

Still's disease is a complex, multisystemic disorder requiring prompt diagnosis and treatment. This study provides a general assessment of a Still's disease cohort aiming to evaluate the efficacy of…

pmc.ncbi.nlm.nih.gov

Dr. John Cush @rheumnow.bsky.social · 2d

Metanalysis of Still's Dz (240 articles, 95 sJIA, 134 AOSD, 23,136 pts); sJIA Dx by ILAR in 78% & AOSD used Yamaguchi criteria 98%. While clinical & lab findings were matched betw AOSD & sJIA, there was variability in MAS , outocmes & trajectory. Standarization needed www.jrheum.org/content/earl...

Clinical Features and Outcome Measures Across Still's Disease (sJIA and AOSD) Cohorts Worldwide: A Systematic Literature Review

Objective Multinational research is essential to improve recognition and management of systemic juvenile idiopathic arthritis (sJIA). Current cohorts vary in the clinical parameters and outcome…

www.jrheum.org

Dr. John Cush @rheumnow.bsky.social · 2d

Multimorbidity in SLE: metanalysis of 3 studies (1175 pts) saw Multimorbidity (by higher Charlson comorbidity index/CCI), is a strong independent predictor of mortality in SLE (OR 3.92). In SLE, the most freq comorbidities were DM, CVD, COPD, renal/lung/CNS Dz www.mdpi.com/2227-9032/13...

www.mdpi.com

Dr. John Cush @rheumnow.bsky.social · 2d

FDA has approved nerandomilast (PDE4b inhibitor) for treatment of adults with idiopathic pulmonary fibrosis (IPF). Approval is based on 2 RCTs, FIBRONEER-IPF & FIBRONEER-ILD, that show slowing of lung function decline IP & progressive pulmonary fibrosis (PPF) pts. www.ajmc.com/view/fda-app...

1

Dr. John Cush @rheumnow.bsky.social · 2d

Optimizing DMARD Therapy in Rheumatoid Arthritis

A phase IV trial from Spain demonstrates that optimization of therapy by lessening biological DMARDs in rheumatoid arthritis (RA) may be feasible, with a low risk of flare.

buff.ly/uswAFw3

Dr. John Cush @rheumnow.bsky.social · 3d

RheumNow is LIVE from #ACR25 Oct 24–29.
KOL perspective videos, clinical-trial highlights, daily recaps & live streaming—all in one feed.

Dr. John Cush @rheumnow.bsky.social · 3d

Sequencing DNA to find new lupus treatments

MUSC geneticist Betty Tsao, Ph.D., will lead a five-year project to identify rare mutations associated with childhood-onset SLE, or lupus, with more than $3.5 million in funding from the NIAMS.

rheumnow.com/news/sequenc...

1

Dr. John Cush @rheumnow.bsky.social · 4d

Associations in Rheumatology (10.3.2025)

Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.

rheumnow.com/news/associa...

Dr. John Cush @rheumnow.bsky.social · 4d

Prospective study of 62 lupus nephritis pts rx w/ induction therapy - MMF vs IV CYC x 6 mos followed by MMF for next 6 mos. At 1 year complete renal remission (CRR) seen in 77% MMF vs 29% CYC. www.theprofesional.com/index.php/tp...

Mycophenolate mofetil versus cyclophosphamide as induction therapy in lupus nephritis at one year- a prospective cohort study. | The Professional Medical Journal

Objective: To compare efficacy of mycophenolate mofetil to intravenous cyclophosphamide as inductive therapy for lupus nephritis at 1 years after induction. Study Design: Observational Prospective…

www.theprofesional.com

1

Dr. John Cush @rheumnow.bsky.social · 4d

Ethnic Minority Rheumatoid Arthritis Consortium registry study of 1315 RA pts (Dz duration 10yrs) incl 29% Blacks found Blacks in less remission(~2-fold by DAS28), more mod-hi dz activity, & frequently met active disease eligibility for RCTs. journals.lww.com/jclinrheum/a...

journals.lww.com

Dr. John Cush @rheumnow.bsky.social · 4d

German survey of 124 AOSD pts - Dz duration 7 yrs (Dx delay 2 yrs), 2/3 on biologics, 84% responding, 81% inactive by CRP. MDs report 35% of pts Sx-free. More Patients report Persistent Sxs LBP (39.5%), fatigue/weakness (39%), & joint inflammation (27%). www.mdpi.com/2077-0383/14...

www.mdpi.com

Dr. John Cush @rheumnow.bsky.social · 4d

Phase 3 RCT Cannabis sativa DKJ127 (VER-1) in 820 chronic low back pain (cLBP) pts. Primary endpt at wk 12 showed pain reduction of −1.9 NRS VER-01 vs −0.6 PBO (P < 0.001). Pain further decreased to −2.9 w/ 6 mos OL Rx. VER-1 was well tolerated. No addiction www.nature.com/articles/s41...

Full-spectrum extract from Cannabis sativa DKJ127 for chronic low back pain: a phase 3 randomized placebo-controlled trial - Nature Medicine

A phase 3 trial found that VER-01, a full-spectrum cannabis extract, reduces chronic low back pain, improves physical function and sleep and shows no signs of dependence or withdrawal.

www.nature.com

Dr. John Cush @rheumnow.bsky.social · 4d

Systematic review of obesity management meds - 56 RCTs (60,307 pts). All OMMs were better at total weight loss than PBO (P < 0.0001), >10% semaglutide & tirzepatide (both effective at NIDDM CHF). Semaglutide effective reducing pain in knee osteoarthritis www.nature.com/articles/s41...

A systematic review and meta-analysis of the efficacy and safety of pharmacological treatments for obesity in adults - Nature Medicine

A systematic review and meta-analysis of clinical trials investigating the efficacy and safety of obesity management medications reported tirzepatide and semaglutide to be the most effective in…

www.nature.com

1

Dr. John Cush @rheumnow.bsky.social · 4d

Activity Trackers Can Predict RA Flares

People with rheumatoid arthritis (RA) who experienced disease flares often showed changes in heart rate and physical activity captured by popular wearable devices 4 weeks before they became clinically apparent, a small study indicated.

buff.ly/wW0rOHs

Dr. John Cush @rheumnow.bsky.social · 5d

FDA Approves Deuruxolitinib for use in adult patients with moderate to severe Alopecia Areata www.ajmc.com/view/fda-app...

FDA Approves Deuruxolitinib for Alopecia Areata | AJMC

The FDA has approved deuruxolitinib, an oral medication developed by Sun Pharma, as the first-line treatment for adults with moderate to severe alopecia areata.

www.ajmc.com